Enhancement of cytotoxicity and clastogenicity of L-DOPA and dopamine by manganese and copper

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 405, Issue 1, 1998, Pages 1-8

  Snyder, Ronald D ^a   Friedman, Mitchell B ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Clastogenesis; Copper; Dopamine; L DOPA; Manganese; Micronucleus; Parkinson's; V79

Indexed keywords

COPPER; CYSTEINE; DOPAMINE; FERRIC ION; GLUTATHIONE; LEVODOPA; MANGANESE; ZINC;

ANIMAL CELL; ARTICLE; CELL DEATH; CELL STRAIN; CONTROLLED STUDY; CYTOTOXICITY; DRUG OXIDATION; HAMSTER; IN VITRO STUDY; MICRONUCLEUS TEST; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMALS; CELL DIVISION; CELL LINE; COPPER; CRICETINAE; CYSTEINE; DOPAMINE; GLUTATHIONE; LEVODOPA; LUNG; MANGANESE; MELANINS; MICRONUCLEUS TESTS; MUTAGENS; PARKINSON DISEASE;

ANIMALIA; CRICETINAE; CRICETULUS GRISEUS;

EID: 0032585055     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(98)00117-1     Document Type: Article

References (24)

1. [1] D.G. Graham, S.M. Tiffany, W.R. Bell Jr., W.T. Gutknecht, Autooxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro, Mol. Pharmacol. 14 (1978) 644-653.
2. [2] S. Fahn, G. Cohen, The oxidant stress hypothesis in Parkinson's disease: evidence supporting it, Ann. Neurol. 32 (1992) 804-812.
3. [3] C.W. Olanow, An introduction to the free radical hypothesis in Parkinson's disease, Ann. Neurol. 32 (1992) S2-S9.
4. [4] I. Ziv, A. Barzilai, D. Offen, R. Stein, A. Achiron, E. Melamed, Dopamine-induced, genotoxic activation of programmed cell death. A role in nigrostriatal neuronal degeneration in Parkinson's disease?, Adv. Neurol. 69 (1996) 229-233.
5. [5] I. Ziv, R. Zilkha-Falb, D. Offen, A. Shirvan, A. Barzilai, E. Melamed, Levodopa induces apoptosis in cultured neuronal cells - A possible accelerator of nigrostriatal degeneration in Parkinson's disease?, Mov. Disord. 12 (1997) 17-23.
6. [6] P. Jenner, Oxidative stress as a cause of Parkinson's disease, Acta Neurol. Scand. 84 (1991) 6-15.
7. [7] M.B.H. Youdim, D. Ben-Schacher, P. Riederer, The possible role of iron in the etiopathology of Parkinson's disease, Mov. Disord. 8 (1993) 1-12.
8. [8] J.M. Gorell, C.C. Johnson, B.A. Rybicki, E.L. Peterson, G.X. Kortsha, G.G. Brown, R.J. Richardson, Occupational exposures to metals as risk factors for Parkinson's disease, Neurology 48 (1997) 650-658.
9. [9] W. Linert, E. Herlinger, R.F. Jameson, E. Kienzl, K. Jellinger, M.B.H. Youdim, Dopamine, 6-hydroxydopamine, iron and dioxygen - their mutual interactions and possible implications in the development of Parkinson's disease, Biochim. Biophys. Acta 1316 (1996) 160-168.
10. [10] M. Parenti, L. Rusconi, V. Cappabianca, E. Parati, A. Gropetti, Role of dopamine in manganese toxicity, Brain Res. 473 (1988) 236-240.
11. [11] E. Josefsson, J. Bergquist, R. Ekman, A. Tarkowski, Catecholamines are synthesized by mouse lymphocytes and regulate function of these cells by induction of apoptosis, Immunology 88 (1996) 140-146.
12. [12] B. Pardo, M.A. Mena, M.J. Casarejos, C.L. Paino, J.G. De Yebenes, Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants, Brain Res. 682 (1995) 133-143.
13. [13] G. Walkinshaw, C.M. Waters, Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease, J. Clin. Invest. 95 (1995) 2458-2464.
14. [14] H. Glatt, Endogenous mutagens derived from amino acids, Mutat. Res. 238 (1990) 235-243.
15. [15] G. Levay, W.J. Bodell, Detection of dopamine - DNA adducts: potential role in Parkinson's disease, Carcinogenesis 14 (1993) 1241-1245.
16. [16] D.B. McGregor, C.G. Riach, A. Brown, I. Edwards, D. Reynolds, K. West, S. Willington, Reactivity of catecholamines and related substances in the mouse lymphoma L5178Y cell assay for mutagens, Environ. Mol. Mutagen. 11 (1988) 523-544.
17. [17] P. Moldeus, M. Nordenskjold, G. Bolcsfoldi, A. Eiche, U. Haglund, B. Lambert, Genetic toxicity of dopamine, Mutat. Res. 124 (1983) 9-24.
18. [18] H.F. Stich, M.P. Rosin, C.H. Wu, W.D. Powrie, The action of transition metals on the genotoxicity of simple phenols, phenolic acids and cinnamic acid, Cancer Lett. 14 (1981) 251-260.
19. [19] W. Suter, I. Matter-Jaeger, Genotoxicity of apomorphine and various catecholamines in the Salmonella mutagenicity test (Ames test) and in tests for primary DNA damage using DNA repair-deficient B. subtilis strains (Rec assay), Mutat. Res. 137 (1984) 17-28.
20. [20] M. Fenech, A.A. Morley, Measurement of micronuclei in human lymphocytes, Mutat. Res. 147 (1985) 29-36.
21. [21] X.-M. Shen, F. Zhang, G. Dryhurst, Oxidation of dopamine in the presence of cysteine: characterization of new toxic products, Chem. Res. Toxicol. 10 (1997) 147-155.
22. [22] M.W. Wick, Levodopa/dopamine analogs as inhibitors of DNA synthesis in human melanoma cells, J. Invest. Dermatol. 92 (1989) 329S-331S.
23. [23] M.W. Wick, Levodopa and dopamine analogs as DNA polymerase inhibitors and antitumor agents in human melanoma, Cancer Res. 40 (1980) 1414-1418.
24. [24] H. Chen, D.A. Eastmond, Topoisomerase inhibition by phenolic metabolites: a potential mechanism for benzene's clastogenic effects, Carcinogenesis 16 (1995) 2301-2307.